Zivo Bioscience Inc
ZIVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.6M
Close$
$-0.53
113.5% downside
Current Fair Value
113.5% downsideOvervalued by 113.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.60 Million |
|---|---|
| Enterprise Value | $17.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.59 |
| Beta | 0.11 |
| Outstanding Shares | 4,150,756 |
Return
| Return on Equity | 162.76% |
|---|---|
| Return on Assets | -1241.30% |
| Return on Invested Capital | 162.52% |
Valuation & Multiples
| P/E Ratio | -3.05 |
|---|---|
| PEG | 4.44 |
| Price to Sales | - |
| Price to Book Ratio | -3.95 |
| Enterprise Value to Revenue | 259.96 |
| Enterprise Value to EBIT | -3.12 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$202,000
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$351,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zivo Bioscience Inc
8 employees
CEO: Andrew Dahl